Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for ILARIS
- A Prevention Trial of Canakinumab in Subjects at High Risk for Lung Cancer
- Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study
- COVID-19 VaccinE Response in Rheumatology Patients
- Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA
- Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial
- A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic PC Patients
- Canakinumab in Patients With COVID-19 and Type 2 Diabetes
- Canakinumab and Azacitidine for the Treatment of Low or Intermediate Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia
- Single Escalating Dose Pilot Trial of Canakinumab (ILARIS®) in Duchenne Muscular Dystrophy
- A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)
- Ilaris (Canakinumab) in Patient With Periodic Fever, Aphthous Stomatitis, Pharyngitis and Cervical Adenitis (PFAPA)
- A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies
- Canakinumab for Treatment of Adult-onset Still's Disease
- Efficacy Study of Canakinumab to Treat Urticaria
- A Pilot Study on the Effects of ILARIS® on Patients With Proliferative Diabetic Retinopathy (PDRP)
- Ilaris® Effects in Schnitzler Syndrome (ILESCH)
- Canakinumab for Pyoderma Gangrenosum
- Efficacy and Safety of Canakinumab in Schnitzler Syndrome
- Ilaris (Canakinumab) in the Schnitzler Syndrome
- A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome / Muckle-Wells Syndrome and Behcet's Disease
- Ilaris® in Urticarial Vasculitis - Investigation of Treatment Responses
Clinical trials list
click for details